HC Wainwright Reiterates “Buy” Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $45.00 target price on the stock.

A number of other analysts have also recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target for the company. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $20.20.

COMPASS Pathways Stock Up 0.8%

Shares of NASDAQ CMPS opened at $3.79 on Monday. COMPASS Pathways has a 12-month low of $2.49 and a 12-month high of $8.54. The stock’s fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $4.00. The stock has a market capitalization of $351.90 million, a PE ratio of -1.72 and a beta of 2.27. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. As a group, analysts expect that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Cerity Partners LLC acquired a new stake in shares of COMPASS Pathways in the 1st quarter valued at about $29,000. GAMMA Investing LLC lifted its holdings in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after buying an additional 5,003 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways during the fourth quarter worth $41,000. Flagship Harbor Advisors LLC raised its holdings in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company’s stock worth $41,000 after purchasing an additional 3,134 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in COMPASS Pathways during the first quarter worth $41,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.